These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 38857379

  • 1. Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis.
    Ivaturi V, Gobburu J, Leslie B, Wang X, Jadhav P.
    Kidney360; 2024 Jul 01; 5(7):996-1001. PubMed ID: 38857379
    [Abstract] [Full Text] [Related]

  • 2. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.
    Am J Kidney Dis; 2015 Jun 01; 65(6):833-41. PubMed ID: 25600953
    [Abstract] [Full Text] [Related]

  • 3. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
    Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.
    J Am Soc Nephrol; 2017 May 01; 28(5):1592-1602. PubMed ID: 27920153
    [Abstract] [Full Text] [Related]

  • 4. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S, Muto S, Kawano H, Okada T, Shibasaki Y, Nakajima K, Ibuki T.
    Clin Exp Nephrol; 2021 May 01; 25(5):467-478. PubMed ID: 33471240
    [Abstract] [Full Text] [Related]

  • 5. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O, TEMPO 3:4 Investigators.
    Kidney Int; 2019 Jul 01; 96(1):159-169. PubMed ID: 30898339
    [Abstract] [Full Text] [Related]

  • 6. A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials.
    Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D.
    Clin J Am Soc Nephrol; 2020 May 07; 15(5):643-650. PubMed ID: 32241780
    [Abstract] [Full Text] [Related]

  • 7. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.
    Uchiyama K, Kitayama C, Yanai A, Ishibashi Y.
    Sci Rep; 2021 Sep 03; 11(1):17666. PubMed ID: 34480075
    [Abstract] [Full Text] [Related]

  • 8. Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.
    Muto S, Okada T, Shibasaki Y, Ibuki T, Horie S.
    Clin Exp Nephrol; 2021 Sep 03; 25(9):1003-1010. PubMed ID: 34089122
    [Abstract] [Full Text] [Related]

  • 9. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT.
    Am J Kidney Dis; 2019 Mar 03; 73(3):354-362. PubMed ID: 30578153
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T, Muto S, Miyake M, Tanaka T, Wang W.
    Clin Exp Nephrol; 2021 Nov 03; 25(11):1231-1239. PubMed ID: 34228250
    [Abstract] [Full Text] [Related]

  • 11. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E, Rodas L, Blasco M, Molina A, Quintana L.
    Drugs Today (Barc); 2018 Sep 03; 54(9):519-533. PubMed ID: 30303493
    [Abstract] [Full Text] [Related]

  • 12. Urinary osmolality in patients with polycystic kidney disease: Measured or calculated?
    Borrego Utiel FJ, Camacho Reina MV, Moriana Domínguez C, Merino García E.
    Nefrologia (Engl Ed); 2020 Sep 03; 40(2):202-204. PubMed ID: 31196658
    [No Abstract] [Full Text] [Related]

  • 13. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M, Kogure Y, Hoshino J, Ubara Y, Mizuno H, Sekine A, Kawada M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Takaichi K.
    J Nephrol; 2018 Dec 03; 31(6):961-966. PubMed ID: 30357715
    [Abstract] [Full Text] [Related]

  • 14. Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?
    Mustafa RA, Yu ASL.
    Clin J Am Soc Nephrol; 2018 Jul 06; 13(7):1107-1109. PubMed ID: 29653956
    [No Abstract] [Full Text] [Related]

  • 15. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
    Moriyama T, Nakayama Y, Soejima M, Yokota Y, Ota K, Ito S, Kodama G, Nakamura N, Kurokawa Y, Yano J, Ueda U, Takamiya Y, Kaida Y, Hazama T, Shibata R, Koda Y, Fukami K.
    Clin Exp Nephrol; 2021 Mar 06; 25(3):251-260. PubMed ID: 33141305
    [Abstract] [Full Text] [Related]

  • 16. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G, Asselin-Thompstone L, Mac-Way F, René de Cotret P, Lacroix C, Desmeules S, Agharazii M.
    Int Urol Nephrol; 2020 Feb 06; 52(2):343-349. PubMed ID: 32008201
    [Abstract] [Full Text] [Related]

  • 17. A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials.
    Stanley IK, Palma AM, Viecelli AK, Johnson DW, Hawley CM, Staatz CE, Mallett AJ.
    J Nephrol; 2024 Jun 06; 37(5):1417-1419. PubMed ID: 38512373
    [No Abstract] [Full Text] [Related]

  • 18. Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?
    Gross P, Schirutschke H, Paliege A.
    Nephrol Dial Transplant; 2019 Jan 01; 34(1):35-37. PubMed ID: 30312449
    [Abstract] [Full Text] [Related]

  • 19. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, TEMPO 3:4 Trial Investigators.
    Clin J Am Soc Nephrol; 2016 May 06; 11(5):803-811. PubMed ID: 26912543
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of Tolvaptan in the Treatment for Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-analysis.
    Xie X, Cai Q, Guo XY, Bai DH, Sheng HZ, Wang BK, Yan K, Lu AM, Wang XR.
    Comb Chem High Throughput Screen; 2020 May 06; 23(1):6-16. PubMed ID: 31793415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.